Post-Essential Thrombocythemia Related Myelofibrosis
Also known as: Post-essential Thrombocythemia Myelofibrosis(Post-ET MF) / Post Essential Thrombocythemia Myelofibrosis (ET-MF) / Thrombocythemia Myelofibrosis (PET-MF) / Post Essential Thrombocythaemia Myelofibrosis / Post-ET Myelofibrosis / Post ET MF / Post Essential Thrombocythemia Myelofibrosis / Myelofibrosis, Post ET / Post-Essential Thrombocythemia (ET) MF / Post-Essential Thrombocythemia Myelofibrosis / Post Essential Thrombocythemia-myelofibrosis / Post- Essential Thrombocythemia Myelofibrosis / Post-Essential Thrombocythemia MF (Post-ET-MF) / Postessential Thrombocythemia (Post-ET) Myelofibrosis / Post-essential Thrombocythemia Myelofibrosis (PET-MF) / Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF) / Post-ET MF / Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) / Post Essential Thrombocythaemia Myelofibrosis (PET-MF) / Myelofibrosis due to and following essential thrombocythemia (disorder) / Myelofibrosis / Myelosis non-leukemic / Agnogenic myeloid metaplasia / Myelofibrosis (disorder) / Myelosis-non-leukaemic / Myelosis non-leukaemic
Drug | Drug Name | Drug Description |
---|---|---|
DB08877 | Ruxolitinib | A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. |